Skip to main content

Advertisement

SpringerLink
Log in

Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

An objective of a large US phase-3 study was to determine the effects of trospium chloride 20-mg tablets versus placebo, administered twice daily, on central nervous system (CNS) adverse events (eg, somnolence) and on daytime sleepiness using the validated Stanford Sleepiness Scale. The impact of age groups also was assessed. Trospium chloride did not increase daytime sleepiness or appear to produce CNS adverse effects, as measured by the Stanford Sleepiness Scale and the incidence of CNS adverse events. Furthermore, there was no difference in these findings across age groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ditropan XL product package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; June 30, 2004.

  2. Kerrebroeck PV, Kreder K, Jonas U: Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414–421.

    Article  PubMed  Google Scholar 

  3. Rudy D, Kline K, Goldberg K: A multicenter, randomized, placebocontrolled trial of trospium chloride in overactive bladder patients [Abstract 144]. Neurourol Urodyn 2004, 23:600–601. Reports on efficacy and safety findings of large, double-blind, placebo-controlled phase-3 study of trospium chloride in patients with overactive bladder.

    CAS  Google Scholar 

  4. Date on file. Indevus Pharmaceuticals, Inc., Lexington, MA.

  5. Pietzko A, Dimpfel W, Schwantes U, et al.: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994, 47:337–343.

    Article  PubMed  CAS  Google Scholar 

  6. Dimpfel W, Todorova A, Vonderheid B: Electrophysiological evaluation of potential adverse effects of tolterodine, oxybutynin, and trospium chloride on the central nervous system [Abstract]. Neurourol Urodyn 2000, 19:497–498.

    Google Scholar 

  7. Herberg KW: General and traffic safety and the effects of incontinence medication: new studies on the safety potential of urological anticholinergics. Die Medizinishce Welt 1999, 50:217–222.

    Google Scholar 

  8. Breuel HP, Murtz G, Bondy S, et al.: Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung 1993, 43:461–464.

    PubMed  CAS  Google Scholar 

  9. Hoddes E, Zarcone V, Smythe H, et al.: Quantification of sleepiness: a new approach. Psychophysiology 1973, 10:431–436. Provides summary of the validation of the Stanford Sleepiness Scale.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Weill-Cornell Medical College, 525 East 68th Street, F-918, 10021, New York, NY, USA

    David R. Staskin MD

Authors
  1. David R. Staskin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark D. Harnett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Staskin, D.R., Harnett, M.D. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 5, 423–426 (2004). https://doi.org/10.1007/s11934-004-0064-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-004-0064-0

Keywords

Search

Navigation